EASD 2020: Editorial Board conference highlights

podcast microphone

Listen to Sanjay Kalra, John Wilding and Lori Berard reflecting on their research highlights of this year’s virtual 56th EASD Annual Meeting. Listen below or subscribe to this podcast on: Spotify | Apple Podcasts | Google Podcasts | Stitcher | TuneIn   About the experts Sanjay Kalra Sanjay Kalra, MBBS MD DM (AIIMS New Delhi), is an endocrinologist based at Bharti Hospital, […]

The DiRECT approach to weight loss: Efficacious and pragmatic

Podcast microphone with soundwave

The DiRECT trial ran counter to received wisdom by advocating a very-low-calorie, total-meal-replacement diet as a means not just of weight loss but also of weight maintenance for people with type 2 diabetes. Trial dietitian Alison Barnes (Newcastle University, UK) speaks of her initial skepticism, and describes how the diet actually worked in practice as […]

The revolution is here: New treatments for diabetic kidney disease

Podcast microphone with soundwave

Speakers: Katherine R Tuttle, Jay H Shubrook Katherine Tuttle and Jay Shubrook reconvene to discuss what the landmark findings from recent renal outcomes trials mean for clinical practice (16:51). About the experts Jay Shubrook Jay H Shubrook, DO, is a Board-Certified Family Physician and Diabetologist. He is a Professor in the Primary Care Department […]

Real-world studies of SGLT2 inhibition and amputation risk

The results of the CANVAS program showed that patients with type 2 diabetes taking canagliflozin had an increased risk for amputation of the toes, feet, or legs, with a rate per 1000 patient–years of 6.3 versus 3.4 in the placebo group. Of note, however, the amputation rate in the CANVAS placebo group was around half of […]

The UKPDS: A lasting legacy

The results of the UK Prospective Diabetes Study (UKPDS) changed the face of diabetes treatment, addressing fundamental questions about the condition, the answers to which still underpin the management of people with diabetes today. And it was a mammoth undertaking, spawning 93 original research papers to date, far exceeding the trialists’ initial expectations for duration […]

A quick guide to the SUSTAIN trials

(Updated June 2021) There are a confusing number of SUSTAIN phase 3 trials either completed or in process, investigating the once-weekly injectable glucagon-like peptide-1 analog semaglutide in patients with type 2 diabetes. The trials are all sponsored by the drug-maker, Novo Nordisk. Here is our guide to the 15 trials launched to date, which are complete, […]